Recombinant human DNase nebulisation in children with cystic fibrosis: Before bedtime or after waking up?

European Respiratory Journal

Volumn 30, Issue 4, 2007, Pages 763-768

  Van Der Giessen, L J ^a,c   Gosselink, R ^b   Hop, W C J ^a   Tiddens, H A W M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c NONE   (Netherlands)

Author keywords

Airway clearance therapy; Children; Cystic fibrosis; Pulmozyme; Recombinant human deoxyribonuclease; Timing

Indexed keywords

ESTERASE; PLACEBO; RECOMBINANT HUMAN DEOXYRIBONUCLEASE; UNCLASSIFIED DRUG; DEOXYRIBONUCLEASE I; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MALE; NEBULIZATION; NIGHT SLEEP; OXYGEN SATURATION; PRIORITY JOURNAL; SAFETY; SIDE EFFECT; SPUTUM; THERAPY EFFECT; WAKEFULNESS; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; NEBULIZER; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TIME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PLACEBOS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 38449097312     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00031107     Document Type: Article

References (37)

1. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1-9.
2. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004; 23: 93-97.
3. Costello CM, O'Connor CM, Finlay GA, Shiels P, FitzGerald MX, Hayes JP. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis. Thorax 1996; 51: 619-623.
4. Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004; 31: 86-91.
5. Morgan WJ, Butler SM, Johnson CA, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the US and Canada. Pediatr Pulmonol 1999; 28: 231-241.
6. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192.
7. Kearney CE, Wallis CE. Deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2000; 2: CD001127.
8. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642.
9. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820.
10. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145-151.
11. Hodson ME, McKenzie S, Harms HK, et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2003; 36: 427-432.
12. ERCF. ERCF Annual Report 1998: F. Hoffmann-La Roche Ltd; 2000.
13. Green JD. Pharmaco-toxicological expert report Pulmozyme rhDNase Genentech, Inc. Hum Exp Toxicol 1994; 13: Suppl. 1, S1-42.
14. Lorrain D, De Koninck J, Dionne H, Goupil G. Sleep Positions and postural shifts in elderly persons. Percept Mot Skills 1986; 63: 352-354.
15. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance in health and disease. Eur Respir J 1999; 13: 1177-1188.
16. Bateman JRM, Pavia D, Clarke SW. The retention of lung secretions during the night in normal subjects. Clin Sci Mol Med 1978; 55: 523-527.
17. Hasani A, Agnew JE, Pavia D, Vora H, Clarke SW. Effect of oral bronchodilators on lung mucociliary clearance during sleep in patients with asthma. Thorax 1993; 48: 287-289.
18. Stokes DC, McBride JT, Wall MA, Erba G, Strieder DJ. Sleep hypoxemia in young adults with cystic fibrosis. Am J Dis Child 1980; 134: 741-743.
19. Pulmozyme. Product monograph update 2. Gardiner-Caldwell Communications, 2002; pp. 3-65.
20. Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995; 89: 499-502.
21. Shah PI, Bush A, Canny GJ, et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Eur Respir J 1995; 8: 954-958.
22. Tiddens HA. Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 2002; 34: 228-231.
23. ICH (1996). International Conference on Harmonisation (ICH) Tripartite Guideline. ICH, Gereva, 1996.
24. Zapletal A, Samanek M, Paul T. Lung Function in Children and Adolescents (Progress in Respiratory Research). Basel, Karger; 1987.
25. Hadjikoumi I, Hassan A, Milner AD. Effects of respiratory timing and cheek support on resistance measurements, before and after bronchodilation in asthmatic children using the interrupter technique. Pediatr Pulmonol 2003; 36: 495-501.
26. Merkus PJ, Mijnsbergen JY, Hop WC, de Jongste JC. Interrupter resistance in preschool children: measurement characteristics and reference values. Am J Respir Crit Care Med 2001; 163: 1350-1355.
27. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
28. Smith J, Owen E, Earis J, Woodcock A. Cough in COPD: correlation of objective monitoring with cough challenge and subjective assessments. Chest 2006; 130: 379-385.
29. Smith JA, Earis JE, Woodcock A. Establishing a gold standard for manual cough counting: video versus digital audio recordings. Cough 2006; 2: 6.
30. Chang AB, Newman RG, Carlin JB, Phelan PD, Robertson CF. Subjective scoring of cough in children: parent-completed vs child-completed diary cards vs an objective method. Eur Respir J 1998; 11: 462-466.
31. Tepper RS, Skatrud JB, Dempsey JA. Ventilation and oxygenation changes during sleep in cystic fibrosis. Chest 1983; 84: 388-393.
32. George CF, West P, Kryger MH. Oxygenation and breathing pattern during phasic and tonic REM in patientswith chronic obstructive pulmonary disease. Sleep 1987; 10: 234-243.
33. Henke KG, Badr MS, Skatrud JB, Dempsey JA. Load compensation and respiratory muscle function during sleep. J Appl Physiol 1992; 72: 1221-1234.
34. van der Schans C. Physiotherapy and Bronchial Mucus Transport. Groningen, Rijksuniversiteit, 1991.
35. van der Giessen LJ, de Jongste JC, Gosselink R, Hop WC, Tiddens HA. RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatr Pulmonol 2007; 42: 624-630.
36. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
37. Widdicombe J, Fontana G. Cough: what's in a name? Eur Respir J 2006; 28: 10-15.